Document is current
Any future updates will be listed below
-
Authors
Rafsani, Fazle
Sheth, Devam
Che, Yiming
Shah, Jay
Siddiquee, Md Mahfuzur Rahman
Chong, Catherine D.
Nikolova, Simona
Ross, Katherine
Dumkrieger, Gina
Li, Baoxin
Wu, Teresa
Schwedt, Todd J.
-
Funding
Funding for this research was provided by:
National Institutes of Health (1R61NS113315-01, 1R61NS113315-01, 1R61NS113315-01, 1R61NS113315-01, 1R61NS113315-01, 1R61NS113315-01, 1R61NS113315-01, 1R61NS113315-01, 1R61NS113315-01, 1R61NS113315-01, 1R61NS113315-01)
U.S. Department of Defense (W81XWH1910534, W81XWH1910534, W81XWH1910534, W81XWH1910534, W81XWH1910534, W81XWH1910534)
Amgen (20187183, 20187183, 20187183)
- License Information
-
More Information
Article History
Received: 5 June 2025
Accepted: 2 September 2025
First Online: 26 September 2025
Declarations
:
: Todd Schwedt, within the prior 24 months, has received consulting fees from AbbVie, Amgen, Linpharma, Lundbeck, Salvia BioElectronics, and Scilex, and royalties from UpToDate. He holds stock options in Allevalux and Nocira. He has received research funding from the American Heart Association, Flinn Foundation, Henry Jackson Foundation, National Headache Foundation, National Institutes of Health, Patient Centered Outcomes Research Institute, Pfizer, Spark Neuro, and United States Department of Defense. Catherine Chong has received research funding from the National Institutes of Health, the American Heart Association and United States Department of Defense.
: This study was approved by the Mayo Clinic Institutional Review Board (IRB), the Phoenix Veterans Administration IRB, and the United States Department of Defense Human Research Protection Office, and all participants provided written informed consent for their participation.
